ASSESSMENT OF ANTIPSYCHOTIC ACTIVITY OF AN UNIQUE AGENT - SU-23397

  • 1 January 1975
    • journal article
    • research article
    • Vol. 1  (2) , 117-122
Abstract
SU-23397 [R(-)-8-[2,3-dihydro-5-methoxy-2-benzofuranyl)methyl]-1-phenyl-1,3,8-triazospiro-[4,5]-decan-4-one] is a unique new hybrid molecule, the animal profile being characteristic of neuroleptic activity. Although the trial was uncontrolled, SU-23397 exerted antipsychotic activity between 20 mg and 250 mg daily in severely ill schizophrenic patients. Seven of the 10 subjects required at least transient antiparkinson medication. Two patients demonstrated premature ventricular contractions [PVCs]. One patient had infrequent PVCs at baseline which increased in frequency with rising dosage. The other patient developed frequent premature ventricular contractions only after active medication was initiated and was subsequently withdrawn from the study.

This publication has 0 references indexed in Scilit: